Retrospective Analysis of Safety and Outcomes of Rituximab for Myasthenia Gravis in Patients ≥ 65 Years Old

2021 ◽  
Author(s):  
Christopher T. Doughty ◽  
Joome Suh ◽  
William S. David ◽  
Anthony A. Amato ◽  
Amanda C. Guidon
2015 ◽  
Vol 49 (5) ◽  
pp. 1510-1515 ◽  
Author(s):  
Jun Nakajima ◽  
Meinoshin Okumura ◽  
Motoki Yano ◽  
Hiroshi Date ◽  
Takuya Onuki ◽  
...  

2021 ◽  
Vol 2 (5) ◽  
Author(s):  
Preston Eibling ◽  
Yuebing Li ◽  
Robert Marquardt

Methotrexate (MTX) is an inexpensive and well-tolerated immunosuppressive medication that is used anecdotally in autoimmune myasthenia gravis (MG). However, the efficacy in MG is unclear at this time. This retrospective analysis describes six patients with acetylcholine receptor antibody positive MG who were treated with MTX and corticosteroids. The efficacy of MTX was measured by steroid-sparing effect and the Myasthenia Gravis Foundation of America (MGFA) classification. MTX initiation was associated with a reduction in prednisone dosage in all patients. Minimal manifestation status was reached at an average duration of 10 months in 5 patients.  No patients were hospitalized for myasthenia gravis exacerbations. There were no major side effects experienced with MTX use.  This retrospective analysis suggests that MTX is safe and probably efficacious as a corticosteroid-sparing agent in the management of MG.


Author(s):  
Nermin Görkem Şirin ◽  
Elif Kocasoy Orhan ◽  
Hacer Durmuş ◽  
Piraye Oflazer ◽  
Yesim Parman ◽  
...  

2021 ◽  
Vol 429 ◽  
pp. 118403
Author(s):  
Eric Qiu Weng Hong ◽  
Tan Seng ◽  
Soong Loong ◽  
Mohd Hafidza Abdul Manaf ◽  
Muhammad Abidin ◽  
...  

1999 ◽  
Vol 47 (03) ◽  
pp. 170-173 ◽  
Author(s):  
M. Klein ◽  
A. Granetzny ◽  
H.-P. Dauben ◽  
H. Schulte ◽  
E. Gams

2018 ◽  
Vol 79 (3-4) ◽  
pp. 113-117 ◽  
Author(s):  
Florencia Aguirre ◽  
Andres M. Villa

Background: We investigated the prognosis of patients with myasthenia gravis (MG) initially presenting with only ocular symptoms in an Argentinian population. Summary: We performed a retrospective analysis of 61 patients with MG with pure ocular involvement at onset. Generalized MG (gMG) developed in 73.7% of patients, while the rest only exhibited ocular symptoms throughout the course of the disease (ocular MG [oMG]). The AChR antibody (AChR-ab) was found in 81.4% of the gMG and 50% of the oMG cases. AChR-ab titers were also significantly higher in the gMG than in the oMG group. Patients with oMG more frequently required treatment only with acetylcholinesterase inhibitors and showed more remissions. Key Messages: Our study showed high generalization in patients with MG debuting with ocular symptoms. Patients with AChR seropositivity and higher AChR-ab titers had an increased risk for gMG, while patients with oMG showed lower corticosteroid requirements and a higher remission rate.


2015 ◽  
Vol 6 (2) ◽  
pp. 195-200 ◽  
Author(s):  
Kimiaki Utsugisawa ◽  
Yuriko Nagane ◽  
Tomihiro Imai ◽  
Masakatsu Motomura ◽  
Masayuki Masuda ◽  
...  

Mediastinum ◽  
2017 ◽  
Vol 1 ◽  
pp. AB043-AB043
Author(s):  
Anna De Rosa ◽  
Roberta Ricciardi ◽  
Michelangelo Maestri ◽  
Melania Guida ◽  
Antonio Chella ◽  
...  

2018 ◽  
Vol 32 (1) ◽  
pp. 325-330 ◽  
Author(s):  
Keerthi Chigurupati ◽  
Shrinivas Gadhinglajkar ◽  
Rupa Sreedhar ◽  
Muraleedharan Nair ◽  
Madathipat Unnikrishnan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document